Comparing Ischemic Cardiovascular Effectiveness and Safety Between Individual SGLT-2 Inhibitors and DPP-4 Inhibitors in Patients with Type 2 Diabetes: a Nationwide Population-based Cohort Study

Overview

Journal Front Pharmacol

Date 2024 Nov 15

PMID 39545068

Authors

Hayeon Kim

Jun-Ho Seo

Jin Hyun Nam

Yejee Lim

Kyung Hee Choi

Kyungim Kim

Affiliations

Soon will be listed here.

Abstract

Objectives: This study compared the ischemic cardiovascular events (iCVEs) effectiveness and safety of initiating empagliflozin or dapagliflozin with those of dipeptidyl peptidase-4 inhibitors (DPP-4is), as well as the comparative effects between empagliflozin and dapagliflozin.

Methods: Using data from the National Health Insurance Service in Korea, patients with type 2 diabetes mellitus (T2DM) who were newly prescribed empagliflozin, dapagliflozin, or DPP-4is from 2016 to 2019 and who did not have a recent CVE history were included. A Cox proportional hazards regression model was used to estimate the adjusted hazard ratio (aHR) with 95% confidence intervals (CIs) for iCVEs and safety events.

Results: Empagliflozin and dapagliflozin significantly reduced the risks of ischemic stroke (aHR 0.568, 95% CI 0.408-0.791; aHR 0.612, 95% CI 0.476-0.786, respectively) and all-cause mortality (aHR 0.590, 95% CI 0.442-0.788; aHR 0.730, 95% CI 0.603-0.884, respectively) compared with DPP-4is. Initiating dapagliflozin or empagliflozin was associated with significantly lower incidence of severe hypoglycemia, bone fracture, urinary tract infection, and acute kidney injury than that of DPP-4is. No significant differences were observed between empagliflozin and dapagliflozin in iCVEs and most safety outcomes.

Conclusion: Empagliflozin and dapagliflozin showed significant preventive effects on ischemic stroke and all-cause mortality compared with DPP-4is in patients with T2DM, and their protective effects were similar. Both empagliflozin and dapagliflozin were not related to the harmful effects on most safety events. These results suggest that it may be beneficial to initiate empagliflozin or dapagliflozin for ischemic stroke prevention in patients with T2DM. However, further validation studies, such as randomized controlled trials, are needed to generalize these results.

References

Persson F, Nystrom T, Jorgensen M, Carstensen B, Gulseth H, Thuresson M . Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: A multinational observational study. Diabetes Obes Metab. 2017; 20(2):344-351. PMC: 5811811. DOI: 10.1111/dom.13077. View

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

Chang H, Weiner J, Richards T, Bleich S, Segal J . Validating the adapted Diabetes Complications Severity Index in claims data. Am J Manag Care. 2012; 18(11):721-6. View

Mannucci E, Monami M . Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?. Drug Saf. 2016; 40(2):115-119. DOI: 10.1007/s40264-016-0470-5. View

Patorno E, Pawar A, Wexler D, Glynn R, Bessette L, Paik J . Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Obes Metab. 2021; 24(3):442-454. PMC: 8939295. DOI: 10.1111/dom.14593. View

Dawwas G, Smith S, Park H . Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Diabetes Obes Metab. 2018; 21(1):28-36. DOI: 10.1111/dom.13477. View

Isaji M . SGLT2 inhibitors: molecular design and potential differences in effect. Kidney Int Suppl. 2011; (120):S14-9. DOI: 10.1038/ki.2010.511. View

ElSayed N, Aleppo G, Aroda V, Bannuru R, Brown F, Bruemmer D . 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care. 2022; 46(Suppl 1):S158-S190. PMC: 9810475. DOI: 10.2337/dc23-S010. View

Blonde L, Patel C, Wu B, Chen Y, Pericone C, Bookhart B . Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States. Adv Ther. 2020; 38(1):594-606. DOI: 10.1007/s12325-020-01549-x. View

10.

Bang O . Considerations When Subtyping Ischemic Stroke in Asian Patients. J Clin Neurol. 2016; 12(2):129-36. PMC: 4828557. DOI: 10.3988/jcn.2016.12.2.129. View

11.

Geerlings S, Fonseca V, Castro-Diaz D, List J, Parikh S . Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria. Diabetes Res Clin Pract. 2014; 103(3):373-81. DOI: 10.1016/j.diabres.2013.12.052. View

12.

Seong S, Kim Y, Khang Y, Park J, Kang H, Lee H . Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2016; 46(3):799-800. PMC: 5837262. DOI: 10.1093/ije/dyw253. View

13.

Elze M, Gregson J, Baber U, Williamson E, Sartori S, Mehran R . Comparison of Propensity Score Methods and Covariate Adjustment: Evaluation in 4 Cardiovascular Studies. J Am Coll Cardiol. 2017; 69(3):345-357. DOI: 10.1016/j.jacc.2016.10.060. View

14.

Kosiborod M, Cavender M, Fu A, Wilding J, Khunti K, Holl R . Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose.... Circulation. 2017; 136(3):249-259. PMC: 5515629. DOI: 10.1161/CIRCULATIONAHA.117.029190. View

15.

Ku E, Lee D, Jeon H, Oh T . Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study. Diabetes Res Clin Pract. 2021; 182:109123. DOI: 10.1016/j.diabres.2021.109123. View

16.

Kashiwagi A, Shoji S, Onozawa S, Kosakai Y, Waratani M, Ito Y . Reduction in cardiovascular disease events in patients with type 2 diabetes mellitus treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world retrospective administrative database analysis in.... J Diabetes Investig. 2022; 13(7):1175-1189. PMC: 9248422. DOI: 10.1111/jdi.13785. View

17.

Kosiborod M, Lam C, Kohsaka S, Kim D, Karasik A, Shaw J . Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. J Am Coll Cardiol. 2018; 71(23):2628-2639. DOI: 10.1016/j.jacc.2018.03.009. View

18.

Meschia J, Bushnell C, Boden-Albala B, Braun L, Bravata D, Chaturvedi S . Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014; 45(12):3754-832. PMC: 5020564. DOI: 10.1161/STR.0000000000000046. View

19.

Scheen A . Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials. Diabetes Metab. 2020; 46(3):186-196. DOI: 10.1016/j.diabet.2020.01.002. View

20.

Ku E, Lee D, Jeon H, Oh T . Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study. Diabetes Res Clin Pract. 2019; 151:65-73. DOI: 10.1016/j.diabres.2019.04.008. View